Search results
Results from the WOW.Com Content Network
If a pregnant woman presents in labor with an unknown HIV status and a positive rapid HIV test result or an infant has a high risk of HIV transmission in utero (for example, the mother was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the mother had not achieved viral suppression, or the mother experienced an ...
The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed the time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped. [58]
Common side effects include headache, tiredness, trouble sleeping, abdominal pain, weight loss, and rash. [5] Serious side effects may include high blood lactate levels and enlargement of the liver. [7] Use of this medication during pregnancy does not appear to harm the fetus, but this has not been well studied. [1]
Common side effects include headaches, fever, and nausea. [6] Serious side effects include liver problems, muscle damage, and high blood lactate levels. [6] It is commonly used in pregnancy and appears to be safe for the fetus. [6] ZDV is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class. [6]
Common side effects include headache, trouble sleeping, sleepiness, and unsteadiness. [5] Serious side effects may include high blood lactate levels, psychiatric symptoms, and enlargement of the liver. [5] It should not be used in children. [7] If used during the first trimester of pregnancy harm to the baby may occur. [5]
Side effects may include trouble sleeping, weight gain, and rash. [2] [3] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. [2] Use remains recommended after the first trimester. [2] Use is not recommended in those with kidney problems. [3]
Lactic acidosis (excess lactic acid in blood) is a rare and potentially fatal side effect. It is characterized by the following symptoms: deep and rapid breathing, tiredness or weakness, nausea, vomiting, abnormal muscle pain, dizziness or drowsiness
The combination is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in people weighing at least 14 kilograms (31 lb) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. [6] [7]